Erlotinib plus either pazopanib or placebo in patients with previously treated advanced non-small cell lung cancer: A randomized, placebo-controlled phase 2 trial with correlated serum proteomic signatures.

Saved in:

Bibliographic Details
Title:	Erlotinib plus either pazopanib or placebo in patients with previously treated advanced non-small cell lung cancer: A randomized, placebo-controlled phase 2 trial with correlated serum proteomic signatures.
Authors:	Spigel, David R.^1,2 dspigel@tnonc.com, Burris, Howard A.^1,2, Greco, F. Anthony^1,2, Shih, Kent C.^1,2, Gian, Victor G.^1,2, Lipman, Andrew J.^1,3, Daniel, Davey B.^1,4, Waterhouse, David M.⁵, Finney, Lindsey¹, Heymach, John V.⁶, Hainsworth, John D.^1,2, Burris, Howard A 3rd^7,8 (AUTHOR)
Source:	Cancer (0008543X). Jun2018, Vol. 124 Issue 11, p2355-2364. 10p.
Database:	Academic Search Ultimate

Description
ISSN:	0008543X
DOI:	10.1002/cncr.31290